Detection of impaired homologous recombination repair in NSCLC cells and tissues

Journal of Thoracic Oncology

Volumn 8, Issue 3, 2013, Pages 279-286

  Birkelbach, Moritz ^a,b   Ferraiolo, Natalie ^a   Gheorghiu, Liliana ^a   Pfäffle, Heike N ^a   Daly, Benedict ^c   Ebright, Michael I ^c   Spencer, Cheryl ^c   O'Hara, Carl ^c   Whetstine, Johnathan R ^a   Benes, Cyril H ^a   Sequist, Lecia V ^a   Zou, Lee ^a   Dahm Daphi, Jochen ^b,d   Kachnic, Lisa A ^a,c   Willers, Henning ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c BOSTON MEDICAL CENTER   (United States)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Biomarker; Homologous recombination; Lung cancer; RAD51

Indexed keywords

ATM PROTEIN; ATR PROTEIN; BRCA1 PROTEIN; CISPLATIN; FANCONI ANEMIA GROUP D2 PROTEIN; GAMMA H2AX; MITOMYCIN; NUCLEAR PROTEIN; OLAPARIB; RAD51 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CANCER TISSUE; CLONOGENESIS; DNA REPAIR; DRUG SENSITIVITY; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; RECOMBINATION REPAIR; TREATMENT RESPONSE;

EID: 84874109205     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31827ecf83     Document Type: Article

References (26)

1. Shepherd FA, Rosell R. Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer. J Thorac Oncol 2007;2:S68-76.
2. Willers H, Pfäffle HN, Zou L. Targeting Homologous Recombination Repair in Cancer. In Kelley MR (ed): DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications. Waltham: Academic Press, Elsevier, 2012, Pp. 119-160.
3. Ferrer M, Span SW, Vischioni B, et al. FANCD2 expression in advanced non-small-cell lung cancer and response to platinum-based chemotherapy. Clin Lung Cancer 2005;6: 250-254.
4. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 2004;23: 1000-1004.
5. Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE 2007;2:e1129.
6. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455: 1069-1075.
7. Kuhnert VM, Kachnic LA, Li L, et al. FANCD2-deficient human fibroblasts are hypersensitive to ionising radiation at oxygen concentrations of 0% and 3% but not under normoxic conditions. Int J Radiat Biol 2009;85: 523-531.
8. Willers H, Taghian AG, Luo CM, Treszezamsky A, Sgroi DC, Powell SN. Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. Mol Cancer Res 2009;7: 1304-1309.
9. Kachnic LA, Fournier L, Gheorghiu L, Rosenberg C, Powell SN, Willers H. Utility of chemotherapy-induced Rad51 foci for the identification of homologous recombination defects in breast cancer cell lines. In Proceedings of the 55th Annual Meeting of the Radiation Research Society, October 4, 2009, Savannah, GA: 99, 2009.
10. Kachnic LA, Li L, Fournier L, Willers H. Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments. Cancer Lett 2010;292: 73-79.
11. Willers H, Kachnic LA, Luo CM, et al. Biomarkers and mechanisms of FANCD2 function. J Biomed Biotechnol 2008;2008: 821529.
12. Yuan SS, Lee SY, Chen G, Song M, Tomlinson GE, Lee EY. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res 1999;59: 3547-3551.
13. Zhang J, Willers H, Feng Z, et al. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol 2004;24: 708-718.
14. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADPribose) polymerase inhibition. Cancer Res 2006;66: 8109-8115.
15. Olive PL, Banáth JP. Kinetics of H2AX phosphorylation after exposure to cisplatin. Cytometry B Clin Cytom 2009;76: 79-90.
16. Sørensen CS, Hansen LT, Dziegielewski J, et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005;7: 195-201.
17. Beucher A, Birraux J, Tchouandong L, et al. ATM and Artemis promote homologous recombination of radiation-induced DNA double-strand breaks in G2. EMBO J 2009;28: 3413-3427.
18. Stiff T, Walker SA, Cerosaletti K, et al. ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling. EMBO J 2006;25: 5775-5782.
19. Garcia-Higuera I, Taniguchi T, Ganesan S, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001;7: 249-262.
20. Schild D, Wiese C. Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability. Nucleic Acids Res 2010;38: 1061-1070.
21. Schlacher K, Wu H, Jasin M. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell 2012;22: 106-116.
22. Graeser M, McCarthy A, Lord CJ, et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2010;16: 6159-6168.
23. Bañuelos CA, Banáth JP, Kim JY, Aquino-Parsons C, Olive PL. gamma- H2AX expression in tumors exposed to cisplatin and fractionated irradiation. Clin Cancer Res 2009;15: 3344-3353.
24. Al-Minawi AZ, Lee YF, Håkansson D, et al. The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links. Nucleic Acids Res 2009;37: 6400-6413.
25. Vaira V, Fedele G, Pyne S, et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci USA 2010;107: 8352-8356.
26. Ibrahim YH, García-García C, Serra V, et al. PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition. Cancer Discov 2012;2: 1036-1047.